Tags

Type your tag names separated by a space and hit enter

Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights.
J Biol Regul Homeost Agents. 2013 Oct-Dec; 27(4):919-33.JB

Abstract

Inflammatory bowel disease (IBD) consists of two distinct clinical forms, ulcerative colitis (UC) and Crohn's disease (CD), with unknown aetiology, which nevertheless are considered to share almost identical pathophysiological backgrounds. Up to date, a full coherent mechanistic explanation for IBD is still lacking, but people start to realize that the pathogenesis of IBD involves four fundamental components: the environment, gut microbiota, the immune system and the genome. As a consequence, IBD development might be due to an altered immune response and a disrupted mechanism of host tolerance to the non-pathogenic resident microbiota, leading to an elevated inflammatory response. Considering the available data arising from the scientific literature, here reviewed, in CD, a benefit of probiotics remains unproven; in UC, a benefit of probiotics remains unproven, even if E. coli Nissle 1917 seems promising in maintaining remission and it could be considered an alternative in patients intolerant or resistant to 5-ASA preparations; in pouchitis, small controlled trials suggest a benefit from VSL no. 3 in the primary and secondary prevention of pouchitis; in IBD-associated conditions, a benefit of probiotics remains unproven. However, well-designed randomized control clinical trials are necessary to understand the undoubted role of these agents in the management of gut physiology in health and disease.

Authors+Show Affiliations

PhD Course in Surgical Biotechnology and Regenerative Medicine, University of Palermo, Italy.Department DICHIRONS, University of Palermo, Italy.Euro-Mediterranean Institute of Science and Technology, Palermo, Italy.Department BIONEC, University of Palermo, Italy.Department DIBIMIS, University of Palermo, Italy.Euro-Mediterranean Institute of Science and Technology, Palermo, Italy.Fondazione Istituto S. Raffaele- G. Giglio, Gastroenterology and Endoscopy Unit, Cefalu', Italy.Fondazione Istituto S. Raffaele- G. Giglio, Gastroenterology and Endoscopy Unit, Cefalu', Italy.Policlinico Paolo Giaccone, Hospital, Unit of Geriatry, Palermo, Italy.Department BIONEC, University of Palermo, Italy.PhD Course in Surgical Biotechnology and Regenerative Medicine, University of Palermo, Italy.PhD Course in Surgical Biotechnology and Regenerative Medicine, University of Palermo, Italy.Department DICHIRONS, University of Palermo, Italy.Department DICHIRONS, University of Palermo, Italy.Institute Paolo Sotgiu for Research in Quantitative and Quantum Psychiatry and Cardiology, LUdeS University, Lugano, Switzerland.Department of Morphology, American University of Beirut, Beirut, Lebanon.Department DICHIRONS, University of Palermo, Italy.PhD Course in Surgical Biotechnology and Regenerative Medicine, University of Palermo, Italy.Fondazione Istituto S. Raffaele- G. Giglio, Gastroenterology and Endoscopy Unit, Cefalu', Italy.

Pub Type(s)

Editorial
Review

Language

eng

PubMed ID

24382173

Citation

Sinagra, E, et al. "Probiotics, Prebiotics and Symbiotics in Inflammatory Bowel Diseases: State-of-the-art and New Insights." Journal of Biological Regulators and Homeostatic Agents, vol. 27, no. 4, 2013, pp. 919-33.
Sinagra E, Tomasello G, Cappello F, et al. Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. J Biol Regul Homeost Agents. 2013;27(4):919-33.
Sinagra, E., Tomasello, G., Cappello, F., Leone, A., Cottone, M., Bellavia, M., Rossi, F., Facella, T., Damiani, P., Zeenny, M. N., Damiani, F., Abruzzo, A., Damiano, G., Palumbo, V. D., Cocchi, M., Jurjus, A., Spinelli, G., Lo Monte, A. I., & Raimondo, D. (2013). Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. Journal of Biological Regulators and Homeostatic Agents, 27(4), 919-33.
Sinagra E, et al. Probiotics, Prebiotics and Symbiotics in Inflammatory Bowel Diseases: State-of-the-art and New Insights. J Biol Regul Homeost Agents. 2013 Oct-Dec;27(4):919-33. PubMed PMID: 24382173.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. AU - Sinagra,E, AU - Tomasello,G, AU - Cappello,F, AU - Leone,A, AU - Cottone,M, AU - Bellavia,M, AU - Rossi,F, AU - Facella,T, AU - Damiani,P, AU - Zeenny,M N, AU - Damiani,F, AU - Abruzzo,A, AU - Damiano,G, AU - Palumbo,V D, AU - Cocchi,M, AU - Jurjus,A, AU - Spinelli,G, AU - Lo Monte,A I, AU - Raimondo,D, PY - 2014/1/3/entrez PY - 2014/1/3/pubmed PY - 2014/5/3/medline SP - 919 EP - 33 JF - Journal of biological regulators and homeostatic agents JO - J. Biol. Regul. Homeost. Agents VL - 27 IS - 4 N2 - Inflammatory bowel disease (IBD) consists of two distinct clinical forms, ulcerative colitis (UC) and Crohn's disease (CD), with unknown aetiology, which nevertheless are considered to share almost identical pathophysiological backgrounds. Up to date, a full coherent mechanistic explanation for IBD is still lacking, but people start to realize that the pathogenesis of IBD involves four fundamental components: the environment, gut microbiota, the immune system and the genome. As a consequence, IBD development might be due to an altered immune response and a disrupted mechanism of host tolerance to the non-pathogenic resident microbiota, leading to an elevated inflammatory response. Considering the available data arising from the scientific literature, here reviewed, in CD, a benefit of probiotics remains unproven; in UC, a benefit of probiotics remains unproven, even if E. coli Nissle 1917 seems promising in maintaining remission and it could be considered an alternative in patients intolerant or resistant to 5-ASA preparations; in pouchitis, small controlled trials suggest a benefit from VSL no. 3 in the primary and secondary prevention of pouchitis; in IBD-associated conditions, a benefit of probiotics remains unproven. However, well-designed randomized control clinical trials are necessary to understand the undoubted role of these agents in the management of gut physiology in health and disease. SN - 0393-974X UR - https://www.unboundmedicine.com/medline/citation/24382173/Probiotics_prebiotics_and_symbiotics_in_inflammatory_bowel_diseases:_state_of_the_art_and_new_insights_ DB - PRIME DP - Unbound Medicine ER -